Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-06-14
2010-11-23
Chong, Kimberly (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S023000, C514S252010, C424S094600
Reexamination Certificate
active
07838561
ABSTRACT:
A method for treating or preventing cardiac hypertrophy in a mammal, comprising manipulating levels of RBP, retinoids, or an affiliated signaling and regulatory pathway in the mammal. Preferably, the method comprises reducing or inhibiting the level of RBP or retinoids or their signaling pathway, or an affiliated signaling pathway, via a dietary, genetic, protein-based, or pharmacologic approach, or a combination thereof. Also disclosed are pharmaceutical composition suitable for the method.
REFERENCES:
Smith et al. Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenyl)retinamide (fenretinide). Jouranl of Nutrition, 1992, vol. 122(10): 1999-2009.
Yamamoto et al. Interactions of Transthyretin (TTR) and Retinol-Binding Protein (RBP) in the Uptake of Retinol by Primary Rat Hepatocytes. Expertimental Cell Research 1997, vol. 234: 373-378.
Green et al. Antisense oligonucleotides: an evolving technology for the modulation of gene, expression in human disease. J Am Coll Surg (2000), vol. 191: 93-105. Elsevier.
Jen et al. Suppresion of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies. Stem Cells (2000), vol. 18:307-319. AlphaMed Press.
Caplen NJ. RNAi as a Gene Therapy Approach. Expert Opinon. Biol. Thera. (2003) vol. 3(4) 575-586. Ashley Publications Ltd.
Novina et al. The RNAi Revolultion. Nature 2004, vol. 430: 161-164. Nature Publishing Group.
Paroo et al. Challenges for RNAi in vivo. Trends in Biotechnology (2004), vol. 22(8) 390-394. Elsevier.
Adams, A. RNA therapeutics enter clinical trials. Scientist (2005), vol. 19:Issue 1. Institute for Scientific Information.
Wang et al. Effects of all-trans retinoic acid on angiostensin II induced myocyte hypertrophy. J. Appl. Physiol 2002, vol. 92, pp. 2162-2168.
de Paiva et al. Ventricular remodeling induced by retinoic acid supplementation in adult rats. Am J Physiol Circ Physiol 2003, vol. 284, pp. H2242-H2246.
Maier et al. Vitamin A for the heart: progress for cardiac hypertrophy regression? Am J Physiol Circ Physiol 2008, vol. 294, pp. H588-H589.
Park et al. Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells.
Blomhoff, Fune. “Transport and metabolism of vitamin A”, Nutrition Reviews, 1994; 52(2), S13.
Cobleigh, Melody A. “Brest Cancer and Fenretinide, an Analogue of Vitamin A”, Leukemia,1994; 8(3), S59-S63, Macmillan Press Ltd, Chicago.
Colbert, Melissa C. “Retinoids and Cardiovascular Development Defects”, Cardiovascular Toxicology.2002, 2(1), 25-39, Humana Press, Cincinnati.
Formelli et al., “Plasma Retinol Level Reduction by the Synthetic Retinoid Fenretinide: A One Year Follow- up Study of Breat Cancer Patients”, Cancer Research. 1989; 49,6149-6152.
Formelli et al., “Five Year Administration of Fenretinide: Pharmacokinetics and Effects on Plasma Retinol Concentrations”, Journal of Clinical Oncology, 1993; 11(10), 2036-2042.
Frey et al.,“Cardiac Hypertrophy: The Good, the Bad, and the Ugly”, Annual Review Physiol 2003; 65, 45-79.
Kaiser-Kupfer et al.,“Abnormal Retinal Function Associated With Fenretinide, a Synthetic Retinoid”, Arch Ophthalmol,1986; 104,69-70.
Kochhar,D M, “The Use of a Retinoid Receptor Antagonist in a New Model to Study Vitamin A-Dependent Developmental Events”, The International Journal of Developmental Biology, 1998; 42(4),601-8.
Moon et al, Influence of 15 Retinoic Acid Amides on Urinary Bladder Carcinogenesis in the Mouse, Carcinogenesis 1982; 3(12), 1469-1472.
Moon et al.,“Inhibition of Carcinogenesis by Retinoids”, Cancer Research(Suppl), 1983; 43,2469s-2475s.
Nagpal et al., “Recent Developments in Receptor-Selective Retinoids”, Current Pharmaceutical Design, 2000;6,919-931.
Napoli,Joseph L, “Biochemical Pathways of Retinoid Transport, Metabolism, and Signal Transduction”, Clinical Immunology and Immunopathology, 1996; 80(3), S52-S62.
Peng et al., “Pharmacokinetics of N-4-Hydroxyphenyl-Retinamide and the Effect of its Oral Administration on Plasma Retinol Concentrations in Cancer Patients”, Int. J. Cancer, 1989; 43,22-26.
Ross,A.Catharine, “Vitamin A: Current Understanding of the Mechanisms of Action”, Nutrition Today, 1991.
Sani et al., “N-(4 Hydroxyphenyl) Retinamide: Internactions with Retinoid-Binding Proteins/Receptors” Carcinogenesis, 1995; 16(10), 2531-2534.
Takahashi et al., “Effects on M5076-Hepatic Metastasis of Retinoic Acd and N-(4-Hydroxyphenyl) Retinamide, Fenretinide Entrapped in SG-Liposomes”, Biol. Pharm. Bull., 2003;26(7), 1060-1063.
Torrisi et al., “The Synthetic Retinoid Fenretinide Lowers Plasma Insulin-like Growth Factor I Levels in Breast Cancer Patients”, Cancer Research 1993; 53, 4769-4771.
Altucci et al., “Leukemia: Beneficial actions of Retinoids and Rexinoids” , The International Journal of Biochemistry & Cell Biology, 2004; 36, 178-182.
Apfel et al., “A Retinoic Acid Receptor α Antagonist Selectively Counteracts Retinoic Acid Effects”, Proc. Natl. Acad. Sci. USA, 1992; 89, 7129-7133.
Conley et al., “Pilot Trial of the Safety, Tolerability, and Retinoid Levels of N-(4 hydroxyphenyl) Retinamid in Combination With Tamoxifen in Patients at High Risk for Developing Invasive Breast Cancer”, Journal of Clinical Oncology, 2000; 18(2)(January), 275-283.
Dimitrov et al. “Alteration of Retinol-Binding-Protein Concentrations by the Synthetic Retinoid Fenretinide in Healthy Human Subjects”, American Journal for Clinical Nutrition, 1990; 51,1082-7.
Giguere, Vincent. , “Retinoic Acid Receptors and Cellular Retinoid Binding Proteins: Complex Interplay in Retinoid Signaling”, Endocrine Reviews, 1994; 15(1), 61-79.
Holven et al., “Secretion of N-(4-Hydroxyphenyl) Retinamide-Retinal-Binding Protein From Liver Parenchymal Cells; Evidence for Reduced Affinity of the Complex for Transthyretin”, Int. J. Cancer, 1997; 71, 654-659.
Klein et al. “Recruitment of Nuclear Receptor Corepressor and Coactivator to the Retinoic Acid Receptor by Retinoid Ligands”, The Journal of Biological Chemistry, 2000; 275(25) (Jun. 23), 19401-19408.
Malpeli et al., “Retinoid Binding to Retinol-Binding Protein and the Interference with the Interaction with transthyretin”, Biochimica et Biophysica Acta, 1996; 1294, 48-54.
Moon et al., “Dietary Retinoids and Carotenoids in Rodent Models of Mammary Tumorigensis”, Breast Cancer Research and Treatment, 1997; 46,11181-189.
Oh et al., “Telomerase Reverse Transcriptase Promotes Cardiac Muscle Cell Proliferation, Hypertrophy, and Survival”, PNAS, 2001; 98(18)(Aug. 28), 10308-10313.
Raffaghelto et al., “Immunoliposomal Fenretinide: A Novel Antitumoral Drug for Human Neuroblastoma”,Cancer Letters, 2003; 197, 151-155.
Zhou et al., “Retinoid-Dependent Pathways Suppress Myocardial Cell Hypertrophy”, Proc. Natl. Acad. Sci. USA, 1995; 92, 7391-7395.
Flentke George R.
Lough John W.
Smith Susan M.
Chong Kimberly
Li Kening
MCW Research Foundation, Inc.
Pinsent Masons LLP
Wisconsin Alumni Research Foundation
LandOfFree
Method for preventing or treating cardiac hypertrophy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing or treating cardiac hypertrophy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing or treating cardiac hypertrophy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4246193